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Abstract
Background: HLA class I and class II alleles have been shown to be associated with the development of dengue
hemorrhagic fever (DHF)/dengue shock syndrome (DSS) in different populations. However, the majority of studies have
been based on limited numbers of patients. In this study we aimed to investigate the HLA-class I and class II alleles that are
positively and negatively associated with the development of DSS in a cohort of patients with DHF and also the alleles
associated with development of DHF during primary dengue infections in a Sri Lankan population.
Methodology/Principal Findings: The allele frequencies of HLA class I and class II alleles were compared in 110 patients
with DHF and 119 individuals from the population who had never reported a symptomatic dengue infection at the time of
recruitment. We found that HLA-A*31 (corrected P=0.01) and DRB1*08 (corrected P=0.009) were associated with
susceptibility to DSS when infected with the dengue virus, during secondary dengue infection. The frequency of DRB1*08
allele was 28.7 times higher than in the normal population in patients with DSS. HLA-A*31 allele was increased 16.6 fold in
DHF who developed shock when compared to those who did not develop shock. A*24 (corrected P=0.03) and DRB1*12
(corrected P=0.041) were strongly associated with the development of DHF during primary dengue infection.
Conclusions/Significance: These data suggest that certain HLA alleles confer susceptibility/protection to severe dengue
infections. As T cell epitope recognition depend on the HLA type of an individual, it would be now important to investigate
how epitope specific T cells associate with primary and secondary dengue infections and in severe dengue infections.
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Introduction
Dengue viral infections have become one of the most important
mosquito borne viral infections in the world and is one of the major
emerging infectious diseases. In the past fifty years, its incidence has
increased 30-fold with significant outbreaks occurring in five of six
WHO regions. It is estimated that 2.1 million cases of dengue
haemorrhagic fever (DHF)/dengue shock syndrome (DSS) occur
every year resulting in 21,000 deaths [1].
Dengue viral infections may be caused by any of the four dengue
virus serotypes (DEN1–4) which are closely related [2]. Initial
infection with a particular serotype is known as primary infection,
which is usually asymptomatic or results in mild disease manifesta-
tions [3]. However, subsequent infection with other serotypes
(secondary dengue infections) may lead to severe disease which
manifests in the form of DHF/DSS [3]. Currently, the pathophys-
iology of dengue viral infections and factors that result in severe
clinical disease is poorly understood. Cross reactive memory T cells
and cross reactive antibodies have been suggested to contribute to
immunopathology by altering the cytokine profiles during secondary
infection and are also believed to be less effective in eliminating the
newly infective virus serotype [4,5]. Therefore, they are thought to
lead to enhanced viral replication and thus severe clinical disease.
Although cross reactive T cells and cross reactive antibodies may
contribute to disease pathogenesis, these mechanisms alone do not
explain the immunopathological mechanisms leading to severe
disease, as severe clinical disease is known to occur even during
primary dengue viral infections, especially infants [6] and in
pregnant women [7]. Furthermore, it is believed that only 0.18–
1% of primary infections and 2–9% of secondary infections manifest
as DHF/DSS [3], and that the majority of individuals who are
infected with the dengue virus develop mild or asymptomatic
disease. Therefore, other factors are likely to play a significant role in
the disease pathogenesis. Several genetic factors have been shown to
be associated with the development of DHF/DSS and some have
been shown to be protective [8,9,10]. Certain HLA- class I and class
II alleles [8,9,11,12], polymorphisms in the tumor necrosis factor
alpha (TNF-a), Vitamin D receptor [13], CTLA-4, and transform-
ing growth factor ß (TGF-b) [14] have been shown to be associated
with development of DHF/DSS [10]. Alleles such as HLA-A*24,
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HLA-DRB1*09, HLA-DR4, HLA-A*03 and HLA-B*18 have been
found to decrease the risk of developing DSS [8,9,15]. Certain HLA
alleles such as HLA-A*51, HLA-A*207 have been shown to increase
the risk of severe DHF only during secondary dengue (SD) infection,
while certain alleles such as HLA-B44, B62, B76 and B77 appeared
to offer some protection [12]. Although Lan et al have also tried to
identify HLA alleles, which may increase the susceptibility for the
development of DSS/severe DHF during primary dengue (PD)
infection, some of the patients who had a PD infection were below
the age of 1 year. Therefore, the presence of maternal antibodies in
these babies could have skewed some of the results and contributed
to occurrence of DHF [8]. These studies are important but have
been limited in most cases by relatively small patient groups.
In this study we aimed to identify possible HLA- class I and class
II alleles, which increase the risk of developing DHF/DSS during
PD and SD infection in a cohort of individuals with DHF. We
found that HLA-A*24 and HLA-DRB1*12 were associated with a
significantly higher risk of developing DHF during PD infection.
In addition, we also found that HLA-A*31 and HLA-DRB1*08
were significantly associated with a higher risk of developing DSS.
These data would support the hypothesis that T cells contribute to




110 patients with clinical features suggestive of dengue
infections were who were admitted to a general medical ward in
a tertiary care hospital in Colombo were enrolled in the study
following informed written consent. The study was approved by
the Ethical Review Committee of the University of Sri
Jayawardanapura and the Ethical review Committee of the
University of Oxford. Serial recordings of their clinical features
and laboratory investigations (platelet counts, haematocrits, white
cell counts) were made until they were discharged from the
hospital in order to determine the severity of dengue infection.
Patients with mild dengue/dengue fever were excluded from the
study, and only patients with dengue haemorrhagic fever (DHF)
(those who had evidence of plasma leakage) were recruited. These
patients were classified as having dengue with warning signs
(moderately severe dengue) and severe dengue according to the
2009 WHO guidelines [16]. Patients with DHF with less than or
equal to a pulse pressure of 20 mmHg were classified as having
shock [16].
HLA types of the normal population was derived from a study
previously done by us [17]. As only 102 individuals (who were
recruited from the Colombo district) were included in our previous
study, we recruited 17 more healthy individuals who so far never
had a symptomatic/clinically diagnosed dengue infection from the
Colombo district. Therefore, HLA types of 119 individuals from
the population were available for comparison with the dengue
patients.
Serology
Dengue virus infection was confirmed by testing the serum
samples which were collected after day 6 of illness with a
commercial capture-IgM and IgG enzyme-linked immunosorbent
assay (ELISA) (Panbio, Brisbane, Australia). The ELISA was
performed and the results were interpreted according to the
manufacturer’s instructions. This ELISA assay has been validated
as both sensitive and specific for primary and secondary dengue
virus infections [18]. Patients who only had dengue virus specific
IgM were classified as having a PD infection while those who had
a positive result for both IgM and IgG were classified as having a
SD infection [16].
HLA typing
HLA class I and class II alleles were typed as previously
described [19]. DNA was extracted from whole EDTA blood
samples from the patients using the QIAamp DNA blood Mini Kit
(QIAGEN, UK). Extracted DNA was amplified and DNA typing
was undertaken using a 144 sequence-specific primer (SSP)
reactions to simultaneously detect all known HLA-A, B, C,
DRB1, DRB3, DRB4, DRB5 and DQB1 specificities in an allele
specific or group specific manner using the same method, reagents,
PCR parameters and protocols for all loci. The PCR products
were electrophoresed in 1.0% agarose gels, using xylene cyanol FF
and bromophenol blue as marker dyes. The gels were run for
15 minutes at 15 V/cm in the 0.56TBE buffer and visualized
using UV illumination [20]. A phototype was considered to be
successful when the control amplifications are positive and at least
one allele or group was present in each locus. Allele frequencies
were estimated from the number of positive typing reactions
divided by the total number of haplotypes tested.
Statistical analysis
The frequencies of HLA class I alleles and HLA class II alleles
in patients with DHF and the normal population were compared
to determine possible association with DHF. Graphpad Prism
version 4 was used for statistical analysis. For each HLA allele,
degree of association between HLA alleles and disease state was
expressed as the odds ratio (OR), which is obtained from standard
contingency table analysis by Haldane’s modification of Woolf’s
method. The Fisher’s exact test was used to determine the p value.
The P values were further corrected by using the Bonferroni’s
inequality method [21]. The corrected P value (Pc) was calculated
by multiplying the p values with the number of alleles tested for
each locus. Comparisons to determine possible alleles that confer
susceptibility to primary dengue infections were done by
comparing the allele frequencies of patients with DHF during
primary infection (n=18) and patients with DHF during
secondary dengue infection (n=92). Comparisons to determine
possible alleles that confer susceptibility to occurrence of shock
during DHF were done by comparing the allele frequencies of
patients with DHF associated with shock (n=29) and patients with
DHF who did not progress to shock (n=81). Only the corrected p
values were used to determine if certain HLA alleles were either
positively or negatively associated with primary dengue or DSS.
All statistical analysis and calculation of P values were done as
described above [9,21].
Results
Clinical characteristics and severity of dengue in the
study population
Of the 110 patients with laboratory confirmed dengue infection,
32 (29.1%) were females. All patients had laboratory evidence of a
rising haematocrit (evidence of plasma leakage) with a concurrent
drop in platelet counts. 50 (45.45%) complained of abdominal
pain and 49 (44.5%) had at least one bleeding manifestation.
Based on the 2009 WHO diagnostic criteria, shock was defined as
lowering of pulse pressure to 20 mmHg or less. Accordingly, 29
patients were classified as having shock. Of the 29 patients who
developed shock, 23 (79.3%) had at least one bleeding manifes-
tation and 5 (17.2%), had episodes of loss of consciousness. 20
(68.9%), of those who developed shock had either haematemesis or
HLA Association in Dengue Viral Infections
PLoS ONE | www.plosone.org 2 June 2011 | Volume 6 | Issue 6 | e20581melana or significant bleeding (vaginal bleeding, epistaxsis or
prolonged bleeding). Their mean platelet counts were 24.2
(SD616.7), whereas the mean platelet counts of those who did
not develop shock was 35.78 (SD635.82). Of the DHF patients
who did not develop shock 26 (32.1%) had at least one bleeding
manifestation and 6 (7.4%) complained of melana and 3 (3.7%)
complained of vaginal bleeding. None of the DHF patients without
shock had haematemesis or severe bleeding.
Based on the presence of dengue specific IgM but no IgG, 18
(16.4%) patients were found to have PD infection. The mean age
of those with PD was 24.7 (SD66.6) and those with SD was 30.1
(SD611.4). 3 (16.6%) patients with PD and 26 (28.2%) of those
with SD developed shock. Bleeding manifestations were present in
9 (50%) of those with PD and 40 (43.4%) of those with SD.
However, only 3 (the 3 patients who developed shock) of those
with PD had a significant bleeding manifestation (melana,
haematemesis, prolong or large bleed) (Table 1).
Associations of HLA class I and II alleles with DHF
The HLA class I and II allele frequency in the normal
population and patients with DHF is shown in table 2. Among the
HLA-A alleles, although not statistically significant after correction
for multiple comparisons, A*68 allele was associated with a
reduced risk of developing DHF (Odds ratio 0.302, CI 0.1096 to
0.8341). HLA-Cw*03 allele was also associated with a reduced risk
of developing DHF (odds ratio 0.544, CI 0.2876 to 1.028), which
was again not statistically significant. HLA-DRB1*08 was strongly
associated with a higher risk of developing DHF (odds ratio 10.11,
CI 1.269 to 80.50). The frequency of this allele in the normal
population was 0.42, whereas the frequency in patients with DHF
was 4.09. However again the association was not statistically
significant (Pc=0.0935).
Associations of HLA class I and II alleles with DHF during
primary dengue infections
The HLA class I and II allele frequency in the normal
population, patients with DHF with PD and SD is shown in
table 3. The allele frequency of HLA-A*24 was 44.44 in DHF with
PD infection, 20.65 in patients with DHF and SD infection and
19.75 in the normal population. This allele was associated with
development of DHF during PD infection (odds ratio 3.074, CI
1.454 to 6.495) which was statistically significant (Pc=0.03).
Among the HLA-B alleles, although not statistically significant,
HLA-B*15 and HLA-B*35 were also associated with a higher risk
of developing DHF during PD infection (odds ratio 2.63 and 2.56
respectively). Interestingly, the HLA-B*51 allele was not present in
the DHF with PD infection, whereas the allele frequency in DHF
patients with SD infection was 8.15 and the frequency in the
normal population was 7.14. HLA-Cw*04 allele was found at a
higher frequency in DHF patients with PD (27.78) than in DHF
patients with SD (15.76) and the normal population (11.76) and it
was associated with a higher risk of developing DHF during PD
(odds ratio 2.056, CI 0.8961 to 4.716). However, again this
association was not statistically significant.
Among the HLA class II alleles, HLA-DRB1*12 was found at a
higher frequency in DHF patients with PD (13.89), when
compared to those with SD (2.17) and normal population (3.78).
This allele was found to be significantly associated with
(Pc=0.041) a higher risk of developing DHF during PD (odds
ratio 7.258, CI 1.846 to 28.54). HLA-DRB1*01 was also found at
a higher frequency among DHF patients with PD (11.11) when
compared to DHF patients with SD (3.8) and the normal
population (5.88). This allele too was found to be associated with
a higher risk of developing DHF during PD (odds ratio 3.161, CI
0.8742 to 11.43), but this association was not statistically
significant (Pc=0.511). The frequency of DQB1*03 was lower
in patients with PD (19.4%), when compared to those with SD
(30.4%) and the normal population (20.6%). However, this
association was not statistically significant.
Associations of HLA class I and II alleles with
development of severe dengue (dengue shock
syndrome)
The HLA class I and II allele frequency in the normal population,
DHF who did not develop shock and DHF with shock is shown in
table 4. HLA-A*31 allele was found to be significantly (Pc=0.01)
associated with the occurrence of shock (odds ratio 18.58, CI 2.185 to
158.0). This allele was increased 16.6 fold in DHF who developed
shock when compared to those who did not develop shock. The
HLA-A*26 allele was not found in any of the patients who developed
shock, whereas the frequency of this allele in the normal population
was 5.46 and in the DHF patients who did not develop shock was








Abdominal pain 6 (33.3) 44 (47.8) 50 (45.5)
Bleeding manifestations 9 (50) 40 (43.5) 49 (44.5))
Petechiae 3 (16.7) 10 (25) 13 (11.8)
Gum bleeding 3 (16.7) 17 (18.5) 20 (18.2)
Prolonged bleeding from sites of venepuncture 2 (11.1) 16 (17.4) 18 (16.4)
Haematemesis 0 (0) 8 (8.6) 8 (7.3)
Melena 3 (16.7) 18 (19.6) 21 (19.1)
Vaginal bleeding 0 (0) 6 (6.5) 6 (5.4)
Pleural effusions 2 (11.1) 15 (16.3) 17 (15.4)
Ascites 1 (5.5) 15 (16.3) 16 (14.5)
Narrow pulse pressure (,20 mmHg) 3 (16.7) 26 (28.3) 29 (26.4)
Platelet count ,20,000 cells/mm
3 5 (27.8) 42 (45.6) 47 (42.7)
doi:10.1371/journal.pone.0020581.t001
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AF (%) Odds ratio CI (95%) PC value
HLA*A
01 10.08 13.18 1.345 0.7617 to 2.406 1.00
02 16.39 14.09 0.837 0.5016 to 1.397 1.00
03 3.78 5.00 1.322 0.5440 to 3.297 1.00
11 10.5 10.9 1.039 0.5766 to 1.888 1.00
24 19.75 24.55 1.322 0.8489 to 2.059 1.00
26 5.46 4.55 0.824 0.3538 to 1.920 1.00
30 1.68 2.73 0.757 0.2801 to 2.005 1.00
31 4.2 3.18 0.759 0.2801 to 2.005 1.00
33 19.33 18.64 0.956 0.5989 to 1.526 1.00
68 7.14 2.27 0.302 0.1096 to 0.8341 0.161
HLA*B
07 7.56 8.18 1.082 0.5513 to 2.152 1.00
08 1.26 1.36 1.082 0.2162 to 5.425 1.00
13 2.1 4.09 1.988 0.6556 to 6.027 1.00
15 8.82 8.64 0.978 0.5101 to 1.871 1.00
18 1.26 1.82 1.451 0.3209 to 6.558 1.00
27 1.68 1.36 0.809 0.1789 to 3.656 1.00
35 10.92 15.45 1.490 0.8622 to 2.577 1.00
37 2.94 3.64 1.245 0.4439 to 3.494 1.00
38 1.68 0.91 0.537 0.09728 to 2.961 1.00
40 12.18 10.00 0.801 0.4450 to 1.441 1.00
44 10.92 11.82 1.093 0.6133 to 1.947 1.00
51 7.14 6.82 0.952 0.4630 to 1.954 1.00
52 5.04 5.91 1.183 0.5277 to 2.651 1.00
55 5.88 4.55 0.755 0.3281 to 1.736 1.00
57 9.24 8.64 0.928 0.4877 to 1.766 1.00
58 7.56 4.55 0.528 0.2626 to 1.290 1.00
HLA*Cw
01 5.88 2.73 0.448 0.1692 to 1.189 1.00
03 12.61 7.27 0.544 0.2876 to 1.028 0.63
04 11.76 17.73 1.616 0.9562 to 2.731 0.852
06 14.29 15.0 1.059 0.6304 to 1.778 1.00
07 24.37 25.91 1.085 0.7112 to 1.656 1.00
08 3.36 3.18 0.945 0.3368 to 2.651 1.00
12 7.98 13.18 1.75 0.9506 to 3.222 1.00
14 2.94 1.36 0.456 0.1165 to 1.787 1.00
15 10.08 9.55 0.942 0.5078 to 1.744 1.00
16 2.94 2.73 0.925 0.3060 to 2.798 1.00
HLA-DRB1*
01 5.88 5.00 0.842 0.3738 to 1.897 1.00
03 4.62 3.18 0.678 0.2581 to 1.782 1.00
04 6.72 8.64 1.312 0.6565 to 2.620 1.00
07 21.01 23.64 1.164 0.7491 to 1.808 1.00
08 0.42 4.09 10.11 1.269 to 80.50 0.0935
10 7.56 7.27 0.957 0.4760 to 1.930 1.00
11 2.10 4.09 1.988 0.6556 to 6.027 1.00
12 3.78 4.09 1.085 0.4227 to 2.786 1.00
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developing shock (odds ratio 0.124, CI 0.007154 to 2.154). However,
this association was not statistically significant (Pc=0.463). Among
the other HLA class I alleles, HLA-B*15 and HLA-B*51 were
increased 2.5foldinpatientswhodeveloped shock whencompared to
t h o s ew h od i dn o t .A l t h o u g hb o t ha l l e l e sw e r ea s s o c i a t e dw i t ha
higher risk of developing shock (odds ratio 2.792, CI 1.073 to 7.267),
this association was not statistically significant (Pc=0.3132). B*07 was












01 10.08 11.11 13.59 0.7950 0.2589 to 2.441 1.00
02 16.39 8.33 15.22 0.5065 0.1453 to 1.766 1.00
11 10.5 5.56 11.96 0.4332 0.09720 to 1.930 1.00
24 19.7 44.44 20.65 3.074 1.454 to 6.495 0.03
26 5.46 2.78 4.89 0.5556 0.06816 to 4.528 1.00
33 19.33 13.89 19.57 0.6631 0.2409 to 1.825 1.00
HLA-B
07 7.56 2.78 9.24 0.2807 0.04129 to 2.189 1.00
15 8.82 16.67 7.07 2.63 0.9275 to 7.462 0.576
35 10.92 27.78 13.04 2.564 1.100 to 5.977 0.243
40 12.18 11.11 9.78 1.153 0.3658 to 3.633 1.00
44 10.92 16.67 10.87 1.640 0.6081 to 4.423 1.00
51 7.14 0 8.15 0.1498 0.00876 to 2.563 0.835
HLA-Cw
03 12.61 11.11 6.52 1.792 0.5434 to 5.908 1.00
04 11.76 27.78 15.76 2.056 0.8961 to 4.716 0.482
06 14.29 11.11 15.76 0.6681 0.2196 to 2.033 1.00
07 24.37 25.00 26.09 0.9444 0.4146 to 2.151 1.00
12 7.98 13.89 13.04 1.075 0.3809 to 3.035 1.00
HLA-DRB1
01 5.88 11.11 3.8 3.161 0.8742 to 11.43 0.511
03 4.62 5.56 2.72 2.106 0.3922 to 11.31 1.00
04 6.72 8.33 8.7 0.9545 0.2631 to 3.463 1.00
07 21.01 13.83 25.54 0.4701 0.1727 to 1.280 1.00
12 3.78 13.89 2.17 7.258 1.846 to 28.54 0.041
13 13.87 16.69 7.07 2.631 0.9275 to 7.462 1.00






AF (%) Odds ratio CI (95%) PC value
13 13.87 8.64 0.587 0.3232 to 1.067 1.00
14 8.4 9.09 1.090 0.5696 to 2.086 1.00
15 21.43 21.36 0.991 0.6370 to 1.558 1.00
HLA-DQB1
02 17.65 15.0 0.823 0.5004 to 1.355 1.00
03 20.59 28.64 1.548 1.008 to 2.378 0.20
05 28.15 27.27 0.957 1.008 to 2.378 1.00
06 29.41 26.82 0.879 0.5846 to 1.323 1.00
doi:10.1371/journal.pone.0020581.t002
Table 2. Cont.
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compared to DHF patients without shock (10.49) and the normal
population (7.56). It was negatively associated with development of
DSS (odds ratio 0.149, CI 0.01945 to 1.151), but this association was
not statistically significant (Pc=0.285). Among the HLA-Cw alleles,
Cw*04 was found at a higher frequency among patients with shock
(20.7%), when compared to those without shock (16.7%) and the
normal population (11.8%). Cw*15 was found at a lower frequency in
patients with shock (5.2%), when compared to those without shock
(11.1%), suggesting that it may be protective. However, both
associations with Cw*04 and Cw*15 were not statistically significant.
HLA-DRB1*08 was strongly associated (Pc=0.009) with the
development of shock (odds ratio 10.98, CI 2.210 to 54.56). The
frequency of this allele among patients with shock was 12.07,
whereas the frequency among DHF without shock was 1.23 and
the frequency in the normal population was 0.42. HLA-DRB1*04
appeared to be protective against shock (odds ratio 0.49) as it was
found at a lower frequency in patients with shock (5.2%), when
compared to those without shock (9.9%). However, this association
was not statistically significant. There were no differences in the
frequencies of the HLA-DQB1 alleles in patients with or without
shock or the normal population.
Discussion
In this study we have identified HLA class I and class II alleles
that are associated with the development of DHF during PD
infection and SD infection and also alleles that are strongly
associated with the development of DSS. The allele frequencies of
patients with DHF were compared with the normal population,
which at the time of recruitment had never reported a
symptomatic/clinically diagnosed dengue infection. However,
given that 72% of children aged 12 years from the Colombo
district in Sri Lanka are seropositive to dengue [22] it is likely that
the majority of individuals who consisted of our normal population
would have had at least one dengue virus infection.
When comparing allele frequencies of patients with DHF and
the normal population, HLA-DRB1*08 allele was associated with
Table 4. Allele frequencies (AF) of the HLA alleles of the normal population, patients with DHF who did not develop shock and




Patients with DHF but no shock
AF (%)
Patients with shock




01 10.08 12.35 15.52 1.304 0.5567 to 3.055 1.00
02 16.39 13.58 15.52 1.169 0.5040 to 2.711 1.00
11 10.50 10.49 12.07 1.171 0.4589 to 2.986 1.00
24 19.75 27.16 17.24 0.5587 0.2601 to 1.200 1.00
26 5.46 6.17 00 0.1241 0.007154 to 2.154 0.463
31 4.2 0.62 10.34 18.58 2.185 to 158.0 0.01
33 19.33 19.75 15.52 0.7462 0.3321 to 1.676 1.00
HLA-B
07 7.56 10.49 1.72 0.149 0.01945 to 1.151 0.285
15 8.82 6.17 15.52 2.792 1.073 to 7.267 0.3132
35 10.92 15.43 15.52 1.007 0.4393 to 2.306 1.00
40 12.18 10.49 8.62 0.8047 0.8047 1.00
44 10.92 12.35 10.34 0.8192 0.3117 to 2.153 1.00
57 9.24 6.17 15.52 2.792 1.073 to 7.267 0.3132
HLA-Cw
03 12.16 7.41 6.9 0.9259 0.2863 to 2.995 1.00
04 11.76 16.67 20.69 1.304 0.6112 to 2.784 1.00
06 14.29 13.58 18.97 1.489 0.6720 to 3.301 1.00
07 24.37 25.93 25.86 0.9967 0.5024 to 1.977 1.00
12 7.98 14.81 8.62 0.5425 0.1967 to 1.496 1.00
15 10.08 11.11 5.17 0.4364 0.1236 to 1.541 1.00
HLA-DRB1
04 6.72 9.88 5.17 0.4977 0.1395 to 1.776 1.00
07 21.01 22.22 27.59 1.333 0.6722 to 2.645 1.00
08 0.42 1.23 12.07 10.98 2.210 to 54.56 0.009
10 7.56 8.02 5.17 0.6252 0.1715 to 2.278 1.00
13 13.87 8.64 8.62 0.9973 0.3426 to 2.903 1.00
14 8.4 9.88 6.9 0.6759 0.2163 to 2.112 1.00
15 21.43 22.84 17.24 0.7038 0.3246 to 1.526 1.00
doi:10.1371/journal.pone.0020581.t004
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the normal population was 0.42, whereas the frequency in
patients with DHF was 4.09. This allele was very strongly
associated with the development of DSS (odds ratio 10.98, CI
2.210 to 54.56). The frequency of this allele among patients with
shock was 12.07, which is 28.7 times higher than in the normal
population. HLA-A*31 allele too was found to be significantly
(Pc=0.01) associated with the occurrence of shock (odds ratio
18.58, CI 2.185 to 158.0). This allele was increased 16.6 fold in
DHF patients who developed shock when compared to those who
did not develop shock. Sierra et al also found that HLA-A*31 was
associated with DHF, but they have not analyzed its association
with DSS/severe clinical disease [23]. However, both HLA-
DRB1*08 and HLA-A*31 were only associated with DSS/DHF
in patients with secondary dengue infection, which possibly
suggests that T cell epitopes directed to this allele could be highly
cross reactive. Mapping and phenotyping T cell epitopes specific
for this allele could possibly reveal disease mechanisms that
contribute to severe dengue infections. Although described by
others [12], we did not find any association with HLA-B*51 or
B*15 [23] and severe dengue infections. However, although not
statistically significant, HLA-B*15 and B*57 were found at a
higher frequency and were positively associated with susceptibil-
ity to DSS (odds ratio 2.79).
HLA-A*24 was found to be strongly associated (Pc=0.03)
with the development of DHF during PD infection (odds ratio
3.074). The allele frequency of HLA-A*24 was 44.44 in DHF
with PD infection and 19.75 in the normal population. Several
studies have shown that A*24 was associated with severe dengue
[8,9,24]. Although not statistically significant, Lan et al also
found that A*24 was associated with a higher risk of developing
DSS/DHF with PD when compared to SD [8]. The other
studies that reported that A*24 was associated with a higher risk
of developing DHF/DSS had not reported the association of
this allele in DHF/DSS patients with PD or SD. Although we
found that A*24 was associated with DHF during PD, it was not
associated with the development of DSS. In fact the allele
frequency in patients with DSS was 17.24, whereas the
frequency in DHF patients without shock was 27.16. Simmons
et al et al also reported that HLA-A*24 T cell epitopes in the
very highly conserved dengue virus NS3 protein have been
identified [20] and are thought to be highly cross reactive [8].
The cross reactivity of this epitope is thought to contribute to
disease pathogenesis [8]. However, the possible contribution of
this allele in the development of DHF during PD infection
cannot be explained by the cross reactivity between A*24
specific dengue virus T cell epitopes. Although several studies
describe the associations of HLA-class I alleles with the
development DHF/DSS, only a few have also described the
associations with HLA-class II alleles. HLA-DRB1*12 allele was
found to be associated (odds ratio 7.26) with the development of
DHF during PD infections. This allele was 6.4 times higher in
DHF patients with PD infection when compared to those with
SD infection.
In the overall comparison of HLA allele frequencies, although not
statistically significant, HLA-A*68 was found to be associated with a
reduced risk of developing DHF (Odds ratio 0.302, CI 0.1096 to
0.8341). This allele was also not detected in DHF with PD and the
allele frequency was 1.72 in patients with DSS (frequency in normal
population was 7.14). Appannna et al also found that this allele was
found at a lower frequency in patients of Indian ethnic origin with
DHF [9]. Again although not statistically significant, HLA-A*26 and
HLA-B*07 were found at a very low frequency in patients with shock
when compared to those who did not develop shock and the normal
population. However, Appanna et al found that in the Malay
population in Malaysia, HLA-A*26 was associated with a higher risk of
developing DHF [9]. Appana et al also described that B *13 was
associated with reduced susceptibility to DSS [9]. This allele was not
detected among our DSS cohort, which probably could imply that it
does reduce susceptibility to DSS. However, as the overall frequency of
this allele in the Sri Lankan population was low, it was not included in
the analysis.
La Fleur et al showed that in the Mexican population, HLA-
DR4 was protective against development of DHF [15]. We too
found that this allele was present at a lower frequency among
patients with DSS. However this was not statistically significant.
DRB1*07 allele has also been shown to be associated with
protection in the Cuban population [23]. We found that the allele
was seen at a lower frequency in patients with DHF during PD
infection and that it was negatively associated with development of
DHF during PD (0.47). However, this association was not
statistically significant. Although Nguyen et al found that HLA-
DRB1*09 was negatively associated with DSS, this allele was not
detected in the Sri Lankan population.
This study was carried out during the largest ever dengue
epidemic in Sri Lanka, which occurred during the years 2009 and
early 2010. Although in this study we have investigated the
association of HLA alleles with primary and secondary dengue
and also in the development of shock, it would have been useful to
determine if infection with a particular dengue virus serotype also
predisposes to shock or DHF during PD and its association with
particular HLA alleles. However, as only adult patients were
recruited in the study, they only presented to hospital with at least
4 to 5 days of fever and were therefore, only recruited to our study
on day 5 of illness. Therefore, they were unsuitable for testing for
the infecting dengue virus serotype.
In summary, in a large cohort of affected individuals, we have
identified HLA class I and class II alleles that are associated with
the development of DHF during PD infection and SD infection
and also alleles that are strongly associated with the development
of DSS. We found that HLA-A*31 and DRB1*08 were associated
with susceptibility to DSS when infected with the dengue virus,
during SD infection. A*24 and DRB1*12 were strongly associated
with the development of DHF during PD infection. As T cell
epitopes to some of these alleles have already been identified, it
would be now important to investigate how epitope specific T cells
could contribute to disease pathogenesis in primary and secondary
dengue infections. Overall these data support a role for T cells in
the pathogenesis of dengue associated disease.
Author Contributions
Conceived and designed the experiments: GNM TR GO. Performed the
experiments: GNM TR ML. Analyzed the data: GNM GO. Contributed
reagents/materials/analysis tools: NF ADDS GO. Wrote the paper: GNM
GO. Provided the patient samples, collected data and clinically diagnosed
patients with acute dengue infection: LTR SDJ.
References
1. Callaway E (2007) Dengue fever climbs the social ladder. Nature 448: 734–735.
2. Weaver SC, Vasilakis N (2009) Molecular evolution of dengue viruses:
contributions of phylogenetics to understanding the history and epidemiology
of the preeminent arboviral disease. Infect Genet Evol 9: 523–540.
3. Mathew A, Rothman AL (2008) Understanding the contribution of cellular
immunity to dengue disease pathogenesis. Immunol Rev 225: 300–313.
4. Dong T, Moran E, Vinh Chau N, Simmons C, Luhn K, et al. (2007) High pro-
inflammatory cytokine secretion and loss of high avidity cross-reactive cytotoxic
HLA Association in Dengue Viral Infections
PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e20581T-cells during the course of secondary dengue virus infection. PLoS One 2:
e1192.
5. Mongkolsapaya J, Duangchinda T, Dejnirattisai W, Vasanawathana S,
Avirutnan P, et al. (2006) T cell responses in dengue hemorrhagic fever: are
cross-reactive T cells suboptimal? J Immunol 176: 3821–3829.
6. Chau TN, Quyen NT, Thuy TT, Tuan NM, Hoang DM, et al. (2008) Dengue
in Vietnamese infants–results of infection-enhancement assays correlate with
age-related disease epidemiology, and cellular immune responses correlate with
disease severity. J Infect Dis 198: 516–524.
7. Waduge R, Malavige GN, Pradeepan M, Wijeyaratne CN, Fernando S, et al.
(2006) Dengue infections during pregnancy: a case series from Sri Lanka and
review of the literature. J Clin Virol 37: 27–33.
8. Nguyen TP, Kikuchi M, Vu TQ, Do QH, Tran TT, et al. (2008) Protective and
enhancing HLA alleles, HLA-DRB1*0901 and HLA-A*24, for severe forms of
dengue virus infection, dengue hemorrhagic fever and dengue shock syndrome.
PLoS Negl Trop Dis 2: e304.
9. Appanna R, Ponnampalavanar S, Lum Chai See L, Sekaran SD (2010)
Susceptible and protective HLA class 1 alleles against dengue fever and dengue
hemorrhagic fever patients in a Malaysian population. PLoS One 5: e13029.
10. Martina BE, Koraka P, Osterhaus AD (2009) Dengue virus pathogenesis: an
integrated view. Clin Microbiol Rev 22: 564–581.
11. Falcon-Lezama JA, Ramos C, Zuniga J, Juarez-Palma L, Rangel-Flores H, et al.
(2009) HLA class I and II polymorphisms in Mexican Mestizo patients with
dengue fever. Acta Trop. pp 193–197.
12. Stephens HA, Klaythong R, Sirikong M, Vaughn DW, Green S, et al. (2002)
HLA-A and -B allele associations with secondary dengue virus infections
correlate with disease severity and the infecting viral serotype in ethnic Thais.
Tissue Antigens 60: 309–318.
13. Loke H, Bethell D, Phuong CX, Day N, White N, et al. (2002) Susceptibility to
dengue hemorrhagic fever in vietnam: evidence of an association with variation
in the vitamin d receptor and Fc gamma receptor IIa genes. Am J Trop Med
Hyg 67: 102–106.
14. Chen RF, Wang L, Cheng JT, Chuang H, Chang JC, et al. (2009) Combination
of CTLA-4 and TGFbeta1 gene polymorphisms associated with dengue
hemorrhagic fever and virus load in a dengue-2 outbreak. Clin Immunol 131:
404–409.
15. LaFleur C, Granados J, Vargas-Alarcon G, Ruiz-Morales J, Villarreal-Garza C,
et al. (2002) HLA-DR antigen frequencies in Mexican patients with dengue virus
infection: HLA-DR4 as a possible genetic resistance factor for dengue
hemorrhagic fever. Hum Immunol 63: 1039–1044.
16. WHO (2009) Dengue guildelines for diagnosis, prevention and control: World
Health Organisation.
17. Malavige GN, Rostron T, Seneviratne SL, Fernando S, Sivayogan S, et al.
(2007) HLA analysis of Sri Lankan Sinhalese predicts North Indian origin.
Int J Immunogenet 34: 313–315.
18. Vaughn DW, Nisalak A, Solomon T, Kalayanarooj S, Nguyen MD, et al. (1999)
Rapid serologic diagnosis of dengue virus infection using a commercial capture
ELISA that distinguishes primary and secondary infections. Am J Trop Med
Hyg 60: 693–698.
19. Bunce M, O’Neill CM, Barnardo MC, Krausa P, Browning MJ, et al. (1995)
Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3,
DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-
specific primers (PCR-SSP). Tissue Antigens 46: 355–367.
20. Simmons CP, Dong T, Chau NV, Dung NT, Chau TN, et al. (2005) Early T-
cell responses to dengue virus epitopes in Vietnamese adults with secondary
dengue virus infections. J Virol 79: 5665–5675.
21. Bland JM, Altman DG (1995) Multiple significance tests: the Bonferroni method.
Bmj 310: 170.
22. Tissera HA, De Silva AD, Abeysinghe MRN, de Silva AM, Palihawadana P,
et al. (2010) Dengue Surveillance in Colombo, Sri Lanka: Baseline seroprev-
alence among children. Procedia in Vaccinology 2: 109–112.
23. Sierra B, Alegre R, Perez AB, Garcia G, Sturn-Ramirez K, et al. (2007) HLA-A,
-B, -C, and -DRB1 allele frequencies in Cuban individuals with antecedents of
dengue 2 disease: advantages of the Cuban population for HLA studies of
dengue virus infection. Hum Immunol 68: 531–540.
24. Loke H, Bethell DB, Phuong CX, Dung M, Schneider J, et al. (2001) Strong
HLA class I–restricted T cell responses in dengue hemorrhagic fever: a double-
edged sword? J Infect Dis 184: 1369–1373.
HLA Association in Dengue Viral Infections
PLoS ONE | www.plosone.org 8 June 2011 | Volume 6 | Issue 6 | e20581